giant cell tumor

Updated: July 15, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

pexidartinib

pexidartinib is indicated in the treatment of tenosynovial giant cell tumor
A dose of 400 mg is administered twice daily on an empty stomach
The medication is continued until the disease is reduced to acceptable toxicity

Dose Adjustments

In case of adverse reactions, the dose is modified or reduced
The pattern of dose reduction goes like this
First dose reduction: 200 mg in the morning and 200 mg in the afternoon
Second dose reduction: 200 mg twice daily
In case the patient is unable to tolerate 200 mg twice daily, discontinue the treatment

denosumab

<13 years or <45kg: :

Safety and efficacy not established
13-17 years (≥45kg): 120 mg subcutaneously every 4 Weeks; give two additional 120 mg doses on Days 8 and 15

Future Trends